{"id":5128,"date":"2025-05-28T09:55:16","date_gmt":"2025-05-28T08:55:16","guid":{"rendered":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/?p=5128"},"modified":"2025-05-28T09:55:16","modified_gmt":"2025-05-28T08:55:16","slug":"world-blood-cancer-day","status":"publish","type":"post","link":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/","title":{"rendered":"Cracking the code of resistance: A new era for myeloma therapy"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" width=\"874\" height=\"570\" class=\"aligncenter size-full wp-image-5131\" src=\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png\" alt=\"Dr Nick Crump\" \/><\/p>\n<p><b><span data-contrast=\"auto\">On World Blood Cancer Day, <a href=\"https:\/\/profiles.imperial.ac.uk\/n.crump\">Dr Nick Crump<\/a>, Kay Kendall Leukaemia Fund Intermediate Fellow in the Hugh and Josseline Langmuir Centre for Myeloma Research, <a href=\"https:\/\/www.imperial.ac.uk\/immunology-inflammation\/\">Department of Immunology and Inflammation<\/a>, shares how new approaches to understanding what causes drug resistance may lead to identifying new treatments.<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<hr \/>\n<p><span data-contrast=\"auto\">Multiple myeloma is the second most common blood cancer. Around 33,000 people are living with myeloma in the UK. Unfortunately, it is currently incurable, and once diagnosed many people live with the disease for the rest of their life. It is more common in people aged over 65, meaning that as the population ages, the number of people with myeloma is expected to rise. At the <\/span><a href=\"https:\/\/www.imperial.ac.uk\/myeloma-research-centre\/\"><span data-contrast=\"none\">Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London<\/span><\/a><span data-contrast=\"auto\">, we are working to better understand myeloma cell behaviour to find new ways to treat myeloma patients.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Several different drugs are available to myeloma patients that can manage and control the disease. Unfortunately, relapse is a big problem, where the cancer comes back months or years after treatment has ended. When the cancer returns, it is often resistant to the previous treatment, meaning that the drugs that worked before are no longer effective for that patient. Therefore, there is a real need to find new drugs for these patients. Our lab is working to understand what causes resistance to myeloma drugs, to look for ways to reverse that resistance and make the treatment effective again.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><!--more--><\/p>\n<p><b><span data-contrast=\"auto\">What makes cancer resistant to treatment?<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">When we think about the changes that happen to turn our healthy cells into cancer cells, we often talk about mutations. These are permanent changes in a cell\u2019s genes, which are the instruction manual for the cell. Because the cell\u2019s instructions have changed, the cell\u2019s behaviour also changes, becoming cancerous. Drug resistance can work in a similar way, making changes to the genes so that the drug stops working. If the drug is a key to unlock a door to kill the cell, a mutation can change the shape of the lock so the key no longer fits.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">However, there is another way that drug resistance can happen. Instead of changing the genetic instructions themselves, the cancer cell can change which instructions it follows. It\u2019s a bit like marking your favourite recipe in a cookbook with a post-it note to use it more often\u2014or writing &#8216;don\u2019t bother&#8217; next to a recipe you don\u2019t like. These are called \u2018epigenetic changes,\u2019 because they sit \u2018on top of\u2019 the genes. Going back to our lock and key idea, rather than changing the lock, the epigenetic change tells the cancer cell to make a bolt to add to the door<\/span><span data-contrast=\"none\">\u2014<\/span><span class=\"TrackChangeTextInsertion TrackedChange SCXW66566441 BCX2\"><span class=\"TextRun SCXW66566441 BCX2\" lang=\"EN-GB\" xml:lang=\"EN-GB\" data-contrast=\"auto\"><span class=\"NormalTextRun CommentHighlightPipeRest SCXW66566441 BCX2\">so the key still fits the lock, but the bolt keeps the door shut.<\/span><\/span><\/span><\/p>\n<p><b><span data-contrast=\"auto\">How can we treat drug resistant myeloma?<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">In my lab, we believe that understanding the epigenetic changes that cause drug resistance may help us to find ways to reverse these changes. If we can stop the cell from making the bolt, the key (our drug treatment) should be able to unlock the door and kill the cancer again. So, we\u2019re working to find out exactly how the myeloma cells place the post-it notes to label the genes that cause resistance. Once we know this, we can develop ways to remove the labels and stop the resistance genes from being used.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The good news is that this approach already seems to be working. A new epigenetic drug called inobrodib is currently being tested in patients with myeloma. \u00a0Although it&#8217;s still early, initial results suggest it may help restore the effectiveness of another drug, pomalidomide, in relapse patients for whom it had stopped working. Our hope is that we can find other drugs that work in a similar way, so that doctors and patients have a choice of treatments they can use.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Of course, drug resistance isn\u2019t only a problem for myeloma patients \u2013 it happens in a lot of blood cancers, and other cancers too. Therefore, we hope that in the future we will be able to use our findings to look beyond myeloma, to see whether what we learn can be used more broadly in cancer treatment.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On World Blood Cancer Day, Dr Nick Crump, Kay Kendall Leukaemia Fund Intermediate Fellow in the Hugh and Josseline Langmuir Centre for Myeloma Research, Department of Immunology and Inflammation, shares how new approaches to understanding what causes drug resistance may lead to identifying new treatments.\u00a0 Multiple myeloma is the second most common blood cancer. Around [&hellip;]<\/p>\n","protected":false},"author":1910,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[302997],"tags":[14855,11192,295901,272423],"class_list":["post-5128","post","type-post","status-publish","format-standard","hentry","category-department-of-immunology-and-inflammation","tag-blood","tag-cancer","tag-drug-resistance","tag-epigenetics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cracking the code of resistance: A new era for myeloma therapy - Imperial Medicine Blog<\/title>\n<meta name=\"description\" content=\"On World Blood Cancer Day, Dr Nick Crump, Kay Kendall Leukaemia Fund Intermediate Fellow in the Hugh and Josseline Langmuir Centre for Myeloma Research, Department of Immunology and Inflammation, shares how new approaches to understanding what causes drug resistance may lead to identifying new treatments.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cracking the code of resistance: A new era for myeloma therapy - Imperial Medicine Blog\" \/>\n<meta property=\"og:description\" content=\"On World Blood Cancer Day, Dr Nick Crump, Kay Kendall Leukaemia Fund Intermediate Fellow in the Hugh and Josseline Langmuir Centre for Myeloma Research, Department of Immunology and Inflammation, shares how new approaches to understanding what causes drug resistance may lead to identifying new treatments.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/\" \/>\n<meta property=\"og:site_name\" content=\"Imperial Medicine Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-28T08:55:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png\" \/>\n\t<meta property=\"og:image:width\" content=\"874\" \/>\n\t<meta property=\"og:image:height\" content=\"570\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Nicholas Crump\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicholas Crump\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/\"},\"author\":{\"name\":\"Nicholas Crump\",\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#\/schema\/person\/f0a5e53e60650dbc1fba3b39ef53ca5d\"},\"headline\":\"Cracking the code of resistance: A new era for myeloma therapy\",\"datePublished\":\"2025-05-28T08:55:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/\"},\"wordCount\":709,\"image\":{\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png\",\"keywords\":[\"Blood\",\"Cancer\",\"Drug resistance\",\"Epigenetics\"],\"articleSection\":[\"Department of Immunology and Inflammation\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/\",\"url\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/\",\"name\":\"Cracking the code of resistance: A new era for myeloma therapy - Imperial Medicine Blog\",\"isPartOf\":{\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png\",\"datePublished\":\"2025-05-28T08:55:16+00:00\",\"author\":{\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#\/schema\/person\/f0a5e53e60650dbc1fba3b39ef53ca5d\"},\"description\":\"On World Blood Cancer Day, Dr Nick Crump, Kay Kendall Leukaemia Fund Intermediate Fellow in the Hugh and Josseline Langmuir Centre for Myeloma Research, Department of Immunology and Inflammation, shares how new approaches to understanding what causes drug resistance may lead to identifying new treatments.\u00a0\",\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#primaryimage\",\"url\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png\",\"contentUrl\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png\",\"width\":874,\"height\":570,\"caption\":\"Dr Nick Crump\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#website\",\"url\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/\",\"name\":\"Imperial Medicine Blog\",\"description\":\"Stories from Imperial&#039;s Faculty of Medicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#\/schema\/person\/f0a5e53e60650dbc1fba3b39ef53ca5d\",\"name\":\"Nicholas Crump\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/59ad3e49c44c8d7a64e8fcadc856b1f59ff17ed17e8074a581f66961891acd8c?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/59ad3e49c44c8d7a64e8fcadc856b1f59ff17ed17e8074a581f66961891acd8c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/59ad3e49c44c8d7a64e8fcadc856b1f59ff17ed17e8074a581f66961891acd8c?s=96&d=mm&r=g\",\"caption\":\"Nicholas Crump\"},\"url\":\"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/author\/ncrump\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cracking the code of resistance: A new era for myeloma therapy - Imperial Medicine Blog","description":"On World Blood Cancer Day, Dr Nick Crump, Kay Kendall Leukaemia Fund Intermediate Fellow in the Hugh and Josseline Langmuir Centre for Myeloma Research, Department of Immunology and Inflammation, shares how new approaches to understanding what causes drug resistance may lead to identifying new treatments.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/","og_locale":"en_GB","og_type":"article","og_title":"Cracking the code of resistance: A new era for myeloma therapy - Imperial Medicine Blog","og_description":"On World Blood Cancer Day, Dr Nick Crump, Kay Kendall Leukaemia Fund Intermediate Fellow in the Hugh and Josseline Langmuir Centre for Myeloma Research, Department of Immunology and Inflammation, shares how new approaches to understanding what causes drug resistance may lead to identifying new treatments.\u00a0","og_url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/","og_site_name":"Imperial Medicine Blog","article_published_time":"2025-05-28T08:55:16+00:00","og_image":[{"width":874,"height":570,"url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png","type":"image\/png"}],"author":"Nicholas Crump","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicholas Crump","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#article","isPartOf":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/"},"author":{"name":"Nicholas Crump","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#\/schema\/person\/f0a5e53e60650dbc1fba3b39ef53ca5d"},"headline":"Cracking the code of resistance: A new era for myeloma therapy","datePublished":"2025-05-28T08:55:16+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/"},"wordCount":709,"image":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png","keywords":["Blood","Cancer","Drug resistance","Epigenetics"],"articleSection":["Department of Immunology and Inflammation"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/","url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/","name":"Cracking the code of resistance: A new era for myeloma therapy - Imperial Medicine Blog","isPartOf":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#primaryimage"},"image":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png","datePublished":"2025-05-28T08:55:16+00:00","author":{"@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#\/schema\/person\/f0a5e53e60650dbc1fba3b39ef53ca5d"},"description":"On World Blood Cancer Day, Dr Nick Crump, Kay Kendall Leukaemia Fund Intermediate Fellow in the Hugh and Josseline Langmuir Centre for Myeloma Research, Department of Immunology and Inflammation, shares how new approaches to understanding what causes drug resistance may lead to identifying new treatments.\u00a0","inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/2025\/05\/28\/world-blood-cancer-day\/#primaryimage","url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png","contentUrl":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/files\/2025\/05\/Screenshot-2025-05-27-at-14.45.54.png","width":874,"height":570,"caption":"Dr Nick Crump"},{"@type":"WebSite","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#website","url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/","name":"Imperial Medicine Blog","description":"Stories from Imperial&#039;s Faculty of Medicine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/#\/schema\/person\/f0a5e53e60650dbc1fba3b39ef53ca5d","name":"Nicholas Crump","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/59ad3e49c44c8d7a64e8fcadc856b1f59ff17ed17e8074a581f66961891acd8c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/59ad3e49c44c8d7a64e8fcadc856b1f59ff17ed17e8074a581f66961891acd8c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/59ad3e49c44c8d7a64e8fcadc856b1f59ff17ed17e8074a581f66961891acd8c?s=96&d=mm&r=g","caption":"Nicholas Crump"},"url":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/author\/ncrump\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pg9uH0-1kI","jetpack_likes_enabled":false,"_links":{"self":[{"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/posts\/5128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/users\/1910"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/comments?post=5128"}],"version-history":[{"count":3,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/posts\/5128\/revisions"}],"predecessor-version":[{"id":5134,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/posts\/5128\/revisions\/5134"}],"wp:attachment":[{"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/media?parent=5128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/categories?post=5128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.imperial.ac.uk\/imperial-medicine\/wp-json\/wp\/v2\/tags?post=5128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}